Thuy D T Vu, Suresh Varadarajan, Ego Seeman, George Jerums, Richard J MacIsaac
Endocrinology Department, Austin Health, Victoria, Australia. thuy.vu@austin.org.au
Current drug safety 2012 AprRaloxifene is an anti-resorptive agent used in postmenopausal osteoporosis. This is the first report of the occurrence of clinically significant hypocalcemia following raloxifene treatment in a patient with occult vitamin D deficiency. Since vitamin D deficiency is widely prevalent in the community, screening for vitamin D deficiency and its correction is advisable before the initiation of anti-resorptive therapy.
Thuy D T Vu, Suresh Varadarajan, Ego Seeman, George Jerums, Richard J MacIsaac. Hypocalcemia induced by raloxifene. Current drug safety. 2012 Apr;7(2):176-8
PMID: 22873502
View Full Text